NasdaqCM - Delayed Quote USD

ASLAN Pharmaceuticals Limited (ASLN)

0.4000 -0.0060 (-1.48%)
At close: 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
12,000.0000
12,000.0000
--
--
--
Gross Profit
12,000.0000
12,000.0000
--
--
--
Operating Expense
55,661.8730
55,661.8730
47,604.7270
33,815.3400
16,182.9870
Operating Income
-43,661.8730
-43,661.8730
-47,604.7270
-33,815.3400
-16,182.9870
Net Non Operating Interest Income Expense
-3,926.6800
-3,926.6800
-3,226.9840
-1,860.7350
-1,246.7390
Other Income Expense
3,501.6160
3,501.6160
-451.4850
4,085.4930
458.4370
Pretax Income
-44,086.9370
-44,086.9370
-51,283.1960
-31,590.5820
-16,971.2890
Tax Provision
132.6670
132.6670
99.2210
--
--
Net Income Common Stockholders
-44,219.6040
-44,219.6040
-51,382.4170
-31,321.6180
-16,197.8890
Diluted NI Available to Com Stockholders
-44,219.6040
-44,219.6040
-51,382.4170
-31,321.6180
-16,197.8890
Basic EPS
-2.75
-2.75
-3.75
-2.50
-2.00
Diluted EPS
-2.75
-2.75
-3.75
-2.50
-2.00
Basic Average Shares
16,449.7060
16,449.7060
13,948.9350
13,027.3710
7,689.0610
Diluted Average Shares
16,449.7060
16,449.7060
13,948.9350
13,027.3710
7,689.0610
Total Operating Income as Reported
-43,735.5970
-43,735.5970
-47,882.4870
-33,846.4520
-16,483.2970
Total Expenses
55,661.8730
55,661.8730
47,604.7270
33,815.3400
16,182.9870
Net Income from Continuing & Discontinued Operation
-44,219.6040
-44,219.6040
-51,382.4170
-31,321.6180
-16,197.8890
Normalized Income
-47,142.3079
-47,142.3079
-51,422.6239
-35,812.0380
-16,653.9840
Interest Income
404.9810
404.9810
448.7050
0.2190
0.5920
Interest Expense
4,326.7830
4,326.7830
3,667.9650
1,860.9540
1,247.3310
Net Interest Income
-3,926.6800
-3,926.6800
-3,226.9840
-1,860.7350
-1,246.7390
EBIT
-39,760.1540
-39,760.1540
-47,615.2310
-29,729.6280
-15,723.9580
EBITDA
-39,411.6560
-39,411.6560
-47,283.4790
-29,447.4040
-15,426.2010
Reconciled Depreciation
348.4980
348.4980
331.7520
282.2240
297.7570
Net Income from Continuing Operation Net Minority Interest
-44,219.6040
-44,219.6040
-51,382.4170
-31,321.6180
-16,197.8890
Total Unusual Items Excluding Goodwill
3,521.3300
3,521.3300
48.4420
4,490.4200
456.0950
Total Unusual Items
3,521.3300
3,521.3300
48.4420
4,490.4200
456.0950
Normalized EBITDA
-42,932.9860
-42,932.9860
-47,331.9210
-33,937.8240
-15,882.2960
Tax Rate for Calcs
0.0002
0.0002
0.0002
--
--
Tax Effect of Unusual Items
598.6261
598.6261
8.2351
--
--
12/31/2020 - 5/4/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TCON TRACON Pharmaceuticals, Inc.
1.9700
-2.48%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.8250
+7.35%
 
TERN Terns Pharmaceuticals, Inc.
5.99
+1.70%
 
RVPHW Reviva Pharmaceuticals Holdings, Inc.
0.3077
-3.84%
 
NRXP NRx Pharmaceuticals, Inc.
3.1800
+6.35%
 
EYEN Eyenovia, Inc.
0.8263
+1.30%
 
ADIL Adial Pharmaceuticals, Inc.
1.4400
-0.35%
 
CNTB Connect Biopharma Holdings Limited
1.9500
+39.29%
 
ALZN Alzamend Neuro, Inc.
0.6000
+18.81%
 
RNAZ TransCode Therapeutics, Inc.
0.7301
+18.48%